Signature HealthCARE Facilities Ranked as America’s Best in Newsweek 2022 Survey
25 janv. 2022 13h17 HE
|
Signature Healthcare
Louisville, Ky., Jan. 25, 2022 (GLOBE NEWSWIRE) -- In the ever-changing environment of long-term care during our nation’s on-going pandemic, the balance between enduring and thriving is a daunting...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
25 janv. 2022 06h45 HE
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
25 janv. 2022 06h45 HE
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Everstream Analytics Supply Chain Risk Solutions Now Available on Oracle Cloud Marketplace
24 janv. 2022 10h00 HE
|
Everstream Analytics
SAN MARCOS, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Everstream Analytics, a leading provider of Supply Chain Risk Analytics and a member of Oracle PartnerNetwork (OPN), today announced that...
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
24 janv. 2022 06h00 HE
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
Given the Current Testing Restraints, Luxor Scientific Reiterates Excess Capacity for COVID-19 Testing
19 janv. 2022 14h02 HE
|
Luxor Scientific, LLC.
GREENVILLE, S.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Luxor Scientific, a full-service clinical testing laboratory that provides laboratory services nationally and for individuals within the region,...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
18 janv. 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
14 janv. 2022 07h30 HE
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Adagio Therapeutics résume l'activité neutralisante de l'ADG20 contre les variants du SARS-CoV-2 et décrit ses initiatives visant à contrer Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Des publications récentes de plusieurs laboratoires indépendants montrent que l'ADG20 a une activité neutralisante présentant une puissance comparable à d'autres anticorps et qui reste active contre...
Adagio Therapeutics 總結 ADG20 對 SARS-CoV-2 變種的中和活性，並概述解決 Omicron 的計劃
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
最近由幾個獨立實驗室發表的刊物顯示 ADG20 具有可與其他抗體相比的效力，具有中和活性，並可保留對 Omicron 的活性 目前正在進行對 Omicron 和潛在未來 SARS-CoV-2 變種的多項努力 麻省沃爾瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI)...